References
- Toyoda K, Yasaka M, Nagata K et al. Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. Cerebrovasc Dis 2009;27:151–9. DOI: 10.1159/000177924.
- Kuramatsu JB, Gerner ST, Schellinger PD et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015;313:824–36. DOI: 10.1001/jama.2015.0846.
- Japan Stroke Society. Guideline 2021 for the Treatment of Stroke (Revised version 2023). Tokyo: Kyowa Kikaku; 2023.
- Pollack CV Jr, Reilly PA, van Ryn J et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017;377:431–41. DOI: 10.1056/NEJMoa1707278.
- Yamashita T, Suzuki S, Inoue H et al. Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. Eur Heart J Qual Care Clin Outcomes 2022;8:202–13.
- Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015;373:2413–24. DOI: 10.1056/NEJMoa1510991.
- Connolly SJ, Crowther M, Eikelboom JW et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2019;380:1326–35. DOI: 10.1056/NEJMoa1814051.
- Carpenter E, Singh D, Dietrich E, Gums J. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Ther Adv 2019;10:1–12.
- Demchuk AM, Yue P, Zotova E et al. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke 2021;52:2096–105. DOI: 10.1161/STROKEAHA.120.030565.
- Costa OS, Connolly SJ, Sharma M et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care 2022;26:180–5.
- Ammar AA, Ammar MA, Owusu KA et al. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage. Neurocrit Care 2021;35:255–61. DOI: 10.1007/s12028-020-01161-5.
- Connolly SJ, Sharma M, Cohen AT et al. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med 2024;390:1745–55. DOI: 10.1056/NEJMoa2313040.
- Milling TJ Jr, Middeldorp S, Xu L et al. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation 2023;147:1026–38. DOI: 10.1161/CIRCULATIONAHA.121.057844.
- Poon MT, Bell SM, Al-Shahi Salman R. Epidemiology of Intracerebral Haemorrhage. Front Neurol Neurosci 2015;37:1. DOI: 10.1159/000437109.
- Martini SR, Flaherty ML, Brown WM et al. Risk factors for intracerebral hemorrhage differ according to hemorrhage location. Neurology 2012;79:2275–82.
- Kurth T, Kase CS, Berger K et al. Smoking and the risk of hemorrhagic stroke in men. Stroke 2003;34:1151.
- Larsson SC, Wallin A, Wolk A et al. Differing association of alcohol consumption with different stroke types: a systematic review and meta-analysis. BMC Med 2016;14:178.
- Wang X, Dong Y, Qi X et al. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 2013;44:1833–9.
- van Asch CJ, Luitse MJ, Rinkel GJ et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010;9:167–75.